You are about to leave this website for another external website outside of the control of Gamida Cell. Gamida Cell has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.
Gamida Cell is developing allogeneic cell therapy products, that are potentially curative, and effective treatments for patients with hematologic malignancies and non-malignant conditions. We are committed to supporting healthcare professionals who care for patients and share our goal of improving clinical outcomes.
Clinical Trials
Gamida Cell’s clinical development candidates are designed to address areas of significant medical need. Read more about our ongoing clinical trials of these investigative therapies and uses below. For more information or questions, please contact us.
Contact Us
OMISIRGE® (omidubicel-onlv) FOR SEVERE APLASTIC ANEMIA
Read MoreOMISIRGE® is being evaluated in an ongoing investigator-sponsored Phase 1/2 study in patients with severe aplastic anemia. For more information about the study, please visit www.clinicaltrials.gov (NCT03173937).
Motixafortide in Sickle Cell Disease stem cell mobilization
Read MoreMotixafortide is being evaluated in an ongoing Phase 1 study in patients with Sickle Cell Disease to determine if it is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. For more information about the study, please visit www.clinicaltrials.gov (NCT06442761).
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD).
Read MoreHSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy. The investigators hypothesize that HSC mobilization with motixafortide (CXCR4i) alone and the combination of motixafortide plus natalizumab (VLA-4i) will be safe and tolerable in SCD patients. In addition, the investigators hypothesize that combined CXCR4 and VLA-4 blockade with motixafortide plus natalizumab will result in a rapid, robust, and synergistic increase in HSC mobilization to peripheral blood (PB) in patients with SCD, when compared to motixafortide alone. For more information about the study, please visit www.clinicaltrials.gov (NCT05618301; Study has finished).
The safety and efficacy of motixafortide in sickle cell disease has not been established by the U.S. Food and Drug Administration or any other health authority.
Scientific Research
Gamida Cell is proud to work with the scientific community to advance research that aligns with our mission of delivering curative new treatments for patients with cancer. For more information on research topics of interest to Gamida Cell, please contact us.
Contact UsGrants & Sponsorships
Gamida Cell is proud to support the scientific community to advance medical education that aligns with our scientific areas of interest. For more information about Gamida Cell medical education grants and sponsorships, please contact us.
Contact Us